These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30030111)

  • 41. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
    Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
    Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
    Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
    Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of three moderate fractionated schedules employed in high-dose-rate brachytherapy monotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2018 Nov; 129(2):370-376. PubMed ID: 30190166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
    Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.
    Gómez-Iturriaga Piña A; Crook J; Borg J; Ma C
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):422-7. PubMed ID: 20832665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
    Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
    Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-Up.
    Yoshioka Y; Suzuki O; Isohashi F; Seo Y; Okubo H; Yamaguchi H; Oda M; Otani Y; Sumida I; Uemura M; Fujita K; Nagahara A; Ujike T; Kawashima A; Yoshida K; Yamazaki H; Nonomura N; Ogawa K
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):675-82. PubMed ID: 26238951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer.
    Yoshida K; Yamazaki H; Nakamara S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y
    Anticancer Res; 2014 Apr; 34(4):2015-8. PubMed ID: 24692740
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.
    Demanes DJ; Martinez AA; Ghilezan M; Hill DR; Schour L; Brandt D; Gustafson G
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1286-92. PubMed ID: 21310546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High dose rate brachytherapy for prostate cancer: A prospective toxicity evaluation of a one day schedule including two 13.5 Gy fractions.
    Nagore G; Lopez Guerra JL; Krumina E; Lagos M; Ovalles B; Miró A; Beltran L; Gómez E; Praena-Fernandez JM; Del Campo ER; Azinovic I; Gomez-Iturriaga A
    Radiother Oncol; 2018 May; 127(2):219-224. PubMed ID: 29625808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-Dose-Rate Monotherapy for Localized Prostate Cancer: 10-Year Results.
    Hauswald H; Kamrava MR; Fallon JM; Wang PC; Park SJ; Van T; Borja L; Steinberg ML; Demanes DJ
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):667-74. PubMed ID: 26443877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer.
    Aluwini S; Busser WM; Alemayehu WG; Boormans JL; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Radiother Oncol; 2015 Nov; 117(2):252-7. PubMed ID: 26409832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate.
    Myers MA; Hagan MP; Todor D; Gilbert L; Mukhopadhyay N; Randolf J; Heimiller J; Anscher MS
    Brachytherapy; 2012; 11(4):292-8. PubMed ID: 22464911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
    Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
    Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
    Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
    Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-fraction brachytherapy as monotherapy for early-stage prostate cancer: The UCSF experience.
    Xu MJ; Chen KS; Chang AJ; Lazar A; Shinohara K; Cunha JAM; Hsu IC
    Brachytherapy; 2019; 18(4):470-476. PubMed ID: 30954399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.